Erratum: Prospective comparative study of intraoperative balloon electronic brachytherapy versus resection with multidisciplinary adjuvant therapy for recurrent glioblastoma

In the article entitled “Prospective comparative study of intraoperative balloon electronic brachytherapy versus resection with multidisciplinary adjuvant therapy for recurrent glioblastoma” published in Surgical Neurology International[1] there are the following figure legend corrections:

- Figure 3 legend is incorrectly written as Kaplan-Meier curves for overall survival in the intraoperative balloon electronic brachytherapy group stratified according to postoperative residual contrast-enhanced volume (PCEV): the subgroup of subjects with PCEV > 2.5 cm³ marked in red, the subgroup of subjects with PCEV ≤ 2.5 cm³ marked in green; log rank $\chi^2 = 8.03$, $P = 0.005$, $P < 0.05$ instead of Kaplan-Meier curves for overall survival in the intraoperative balloon electronic brachytherapy group stratified according to postoperative residual contrast-enhanced volume (PCEV): the subgroup of subjects with PCEV > 2.5 cm³ marked in green, the subgroup of subjects with PCEV ≤ 2.5 cm³ marked in red; log rank $\chi^2 = 8.03$, $P = 0.005$, $P < 0.05$.

- Figure 4 legend is incorrectly written as Kaplan-Meier curves for overall survival: The intraoperative balloon electronic brachytherapy group marked in green, the control group marked in red; Log Rank $\chi^2 = 4.23$, $P = 0.04$, $P < 0.05$ instead of Kaplan-Meier curves for overall survival: The intraoperative balloon electronic brachytherapy group marked in red, the control group marked in green; Log Rank $\chi^2 = 4.23$, $P = 0.04$, $P < 0.05$.

- Figure 5 legend is incorrectly written as Kaplan-Meier curves for local progression-free survival: the intraoperative balloon electronic brachytherapy group marked in green, the control group marked in red, Log Rank $\chi^2 = 4.93$, $P = 0.026$, $P < 0.05$ instead of Kaplan-Meier curves for local progression-free survival: the intraoperative balloon electronic brachytherapy group marked in red, the control group marked in green, Log Rank $\chi^2 = 4.93$, $P = 0.026$, $P < 0.05$.

- Figure 6 legend is incorrectly written as Kaplan-Meier curves for overall survival in the subgroups of subjects with postoperative residual contrast-enhanced volume ≤ 2.5 cm³: the intraoperative balloon electronic brachytherapy group marked in green, the control group marked in red; Log Rank $\chi^2 = 4.13$, $P = 0.042$, $P < 0.05$ instead of Kaplan-Meier curves for overall survival in the subgroups of subjects with postoperative residual contrast-enhanced volume ≤ 2.5 cm³: the intraoperative balloon electronic brachytherapy group marked in red, the control group marked in green; Log Rank $\chi^2 = 4.13$, $P = 0.042$, $P < 0.05$. 

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
• Figure 7 legend is incorrectly written as Kaplan-Meier curves for local progression-free survival in the subgroups of subjects with postoperative residual contrast-enhanced volume ≤2.5 cm³: the intraoperative balloon electronic brachytherapy group marked in green, the control group marked in red; Log Rank $\chi^2 = 7.24$, $P = 0.007$, $P < 0.05$ instead of Kaplan-Meier curves for local progression-free survival in the subgroups of subjects with postoperative residual contrast-enhanced volume ≤2.5 cm³: the intraoperative balloon electronic brachytherapy group marked in red, the control group marked in green; Log Rank $\chi^2 = 7.24$, $P = 0.007$, $P < 0.05$.

• In Tables 3 and 5 Current status is incorrectly written as October 2020 instead of March 2021.

REFERENCE

1. Krivoshapkin A, Gaytan A, Abdullaev O, Salim N, Sergeev G, Marmazeev I, et al. Prospective comparative study of intraoperative balloon electronic brachytherapy versus resection with multidisciplinary adjuvant therapy for recurrent glioblastoma. Surg Neurol Int 2021;12:517.